Geschwind Jean-Francois H, Ko Young H, Torbenson Michael S, Magee Carolyn, Pedersen Peter L
Division of Cardiovascular and Interventional Radiology, The Russell H. Morgan Department of Radiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205-2185, USA.
Cancer Res. 2002 Jul 15;62(14):3909-13.
Most types of cancer are difficult to eradicate and some, like liver carcinomas, are almost always fatal. Significantly, we report here that direct intraarterial delivery of 3-bromopyruvate (3-BrPA), a potent inhibitorof cell ATP production, to liver-implanted rabbit tumors, inflicts a rapid, lethal blow to most cancer cells therein. Moreover, systemic delivery of 3-BrPA suppresses "metastatic" tumors that arise in the lungs. In both cases, there is no apparent harm to other organs or to the animals. Thus, intraarterial delivery of agents like 3-BrPA directly to the site of the primary tumor, followed by systemic delivery only when necessary, may represent a powerful new strategy for arresting the growth of liver and other cancers while minimizing toxic side effects.
大多数类型的癌症难以根除,有些癌症,如肝癌,几乎总是致命的。值得注意的是,我们在此报告,将细胞ATP生成的强效抑制剂3-溴丙酮酸(3-BrPA)经动脉直接注入植入肝脏的兔肿瘤中,会对其中的大多数癌细胞造成迅速的致命打击。此外,全身性给予3-BrPA可抑制肺部出现的“转移性”肿瘤。在这两种情况下,对其他器官或动物均无明显损害。因此,将3-BrPA等药物经动脉直接输送到原发性肿瘤部位,仅在必要时进行全身性给药,可能代表一种强大的新策略,既能阻止肝癌和其他癌症的生长,又能将毒副作用降至最低。